Zobrazeno 1 - 10
of 32
pro vyhledávání: '"BUZDAR, A"'
Autor:
Dowsett, M, Forbes, JF, Bradley, R, Ingle, J, Aihara, T, Bliss, J, Boccardo, F, Coates, A, Coombes, RC, Cuzick, J, Dubsky, P, Gnant, M, Kaufmann, M, Kilburn, L, Perrone, F, Rea, D, Thuerlimann, B, Van de Velde, C, Pan, H, Peto, R, Davies, C, Gray, R, Baum, M, Buzdar, A, Sestak, I, Markopoulos, C, Fesl, C, Jakesz, R, Colleoni, M, Gelber, R, Regan, M, Von Minckwitz, G, Snowdon, C, Goss, P, Pritchard, K, Anderson, S, Costantino, J, Mamounas, E, Ohashi, Y, Watanabe, T, Bastiaannet, E
Publikováno v:
Lancet, 386(10001), 1341-1352. Elsevier Science
Lancet, 386(10001), 1341-1352. Elsevier Limited
2015, ' Aromatase inhibitors versus tamoxifen in early breast cancer : patient-level meta-analysis of the randomised trials ', The Lancet, vol. 386, no. 10001, pp. 1341-52 . https://doi.org/10.1016/S0140-6736(15)61074-1
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) & Clarke, M 2015, ' Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials ', Lancet, vol. 386, no. 10001, pp. 1341–1352 . https://doi.org/10.1016/S0140-6736(15)61074-1
Lancet, 386(10001), 1341-1352
LANCET, 386(10001), 1341-1352. ELSEVIER SCIENCE INC
Lancet, 386(10001), 1341-1352. Elsevier Limited
2015, ' Aromatase inhibitors versus tamoxifen in early breast cancer : patient-level meta-analysis of the randomised trials ', The Lancet, vol. 386, no. 10001, pp. 1341-52 . https://doi.org/10.1016/S0140-6736(15)61074-1
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) & Clarke, M 2015, ' Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials ', Lancet, vol. 386, no. 10001, pp. 1341–1352 . https://doi.org/10.1016/S0140-6736(15)61074-1
Lancet, 386(10001), 1341-1352
LANCET, 386(10001), 1341-1352. ELSEVIER SCIENCE INC
Background The optimal ways of using aromatase inhibitors or tamoxifen as endocrine treatment for early breast cancer remains uncertain.Methods We undertook meta-analyses of individual data on 31 920 postmenopausal women with oestrogen-receptor-posit
Autor:
Kathy R. Brandt, Aman U. Buzdar, Richard M. Weinshilboum, Celine M. Vachon, Janet E. Olson, Paul E. Goss, Daniel J. Serie, Fang Fang Wu, VJ Suman, Lois E. Shepherd, JN Ingle, Matthew L. Kosel
Publikováno v:
Cancer Research. 70:P2-09
Background: Mammographic density, the variation in fat, epithelial and stromal tissues seen on screening mammography, is a strong risk factor for breast cancer and can be modified by hormonal agents. Changes in density from tamoxifen or postmenopausa
Publikováno v:
Core Evidence
Introduction: Endocrine therapy is an important and integral part of breast cancer management. Selective estrogen receptor modulators (SERMs), such as tamoxifen, remain a vital component in the endocrine therapy armamentarium. However the “ideal SE
Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer
Autor:
John F. Forbes, Walter Jonat, Aman U. Buzdar, Jack Cuzick, Rowan T. Chlebowski, Sean Duffy, Peter M. Ravdin
Publikováno v:
Current Medical Research and Opinion. 22:1575-1585
Over the past few years, data have been published concerning the relative efficacy and safety profiles of tamoxifen and the aromatase inhibitors (AIs) in the adjuvant therapy setting for women with early hormone receptor-positive breast cancer. Recen
Autor:
Aman U. Buzdar
Publikováno v:
Expert Review of Anticancer Therapy. 6:839-848
Third-generation aromatase inhibitors are accepted widely as alternatives to tamoxifen for the treatment of advanced breast cancer in postmenopausal women and, currently, are increasingly replacing tamoxifen in the adjuvant setting. This drug profile
Autor:
Aman U. Buzdar, Jack Cuzick
Publikováno v:
Clinical Cancer Research. 12:1037s-1048s
The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial compared the efficacy and safety of anastrozole versus tamoxifen versus the combination as initial adjuvant treatment for early breast cancer in over 9,000 postmenopausal women. Analyses a
Autor:
Anthony Howell, Aman U. Buzdar
Publikováno v:
The Journal of Steroid Biochemistry and Molecular Biology. 93:237-247
Aromatase inhibitors (AIs) have been in use to treat metastatic breast cancer for over 25 years. Recently potent and specific AIs have been introduced, which, because of their low toxicity profile, are being used in the adjuvant and neoadjuvant situa
Autor:
Aman U. Buzdar
Publikováno v:
The Oncologist. 8:335-341
Learning Objectives After completing this course, the reader will be able to: Define appropriate candidates for various endocrine therapies. Discuss the choices of therapies for patients with advanced breast cancer. Assess the options for adjuvant en
Autor:
Eleftherios P. Mamounas, Michael Baum, Mitchell Dowsett, Anthony Howell, Generosa Grana, Robert W. Carlson, Richard M. Elledge, William J. Gradishar, D. Craig Allred, Aman U. Buzdar
Publikováno v:
The Breast Journal. 9:213-222
This article summarizes the conclusions of a meeting of diverse breast cancer experts who discussed issues, controversies, and new clinical trial results relevant to the use of aromatase inhibitors for treating postmenopausal women with breast cancer
Autor:
Daniel J. Booser, Stephen E. Jones, Eric P. Winer, Allen S. Melemed, Aman U. Buzdar, Patrick Peterson, John E. Pippen, Joyce A. O'Shaughnessy, Clifford A. Hudis, Pamela N. Munster
Publikováno v:
Journal of Clinical Oncology. 21:1007-1014
Purpose: To select a daily dose of arzoxifene ( LY353381 ), a selective estrogen receptor modulator, for use in future studies in women with locally advanced or metastatic breast cancer who are either potentially tamoxifen sensitive (TS) or tamoxifen